A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
GlaucomaOcular Hypertension
Interventions
DRUG

Fixed-Combination Bimatoprost/Brimonidine

One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.

DRUG

Bimatoprost Ophthalmic Solution 0.01%

One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.

DRUG

Vehicle Ophthalmic Solution

One drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.

DRUG

Brimonidine Tartrate Ophthalmic Solution 0.2%

One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.

Trial Locations (1)

Unknown

Newport Beach

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY